Bruker Corporation (BKD.F)
| Previous Close | 73.04 |
| Open | 73.02 |
| Bid | 73.02 x 60000 |
| Ask | 73.96 x 60000 |
| Day's Range | 73.02 - 73.02 |
| 52 Week Range | 51.50 - 86.50 |
| Volume | |
| Avg. Volume | 54 |
| Market Cap | 10.053B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | 26.75 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.18 (0.23%) |
| Ex-Dividend Date | Feb 29, 2024 |
| 1y Target Est | N/A |
- Business Wire
Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates
ASILOMAR, Calif., April 08, 2024--Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.
- Business Wire
Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies
ASILOMAR, Calif., April 08, 2024--Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
- GlobeNewswire
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
Strategic partnership expands Biognosys’ services to include Alamar’s NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys’ DIA-MS unbiased proteomics platform and Alamar’s game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company po
